Portola Pharmaceuticals Inc (NASDAQ:PTLA) – Analysts at Oppenheimer dropped their Q1 2018 earnings per share (EPS) estimates for Portola Pharmaceuticals in a research note issued to investors on Wednesday. Oppenheimer analyst J. Olson now forecasts that the biopharmaceutical company will post earnings per share of ($1.72) for the quarter, down from their prior estimate of ($1.42). Oppenheimer currently has a “Buy” rating and a $80.00 target price on the stock. Oppenheimer also issued estimates for Portola Pharmaceuticals’ Q2 2018 earnings at ($0.15) EPS, Q3 2018 earnings at ($1.61) EPS, FY2018 earnings at ($4.81) EPS, FY2019 earnings at ($0.33) EPS and FY2020 earnings at $3.63 EPS.
PTLA has been the subject of several other research reports. BidaskClub upgraded shares of Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. Goldman Sachs Group initiated coverage on shares of Portola Pharmaceuticals in a research report on Friday, December 1st. They set a “buy” rating and a $75.00 price target for the company. ValuEngine upgraded shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research lowered shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, January 4th. Finally, William Blair restated a “buy” rating on shares of Portola Pharmaceuticals in a research report on Monday, January 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $70.65.
In other Portola Pharmaceuticals news, Director Henry Ward Wolff sold 12,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $47.00, for a total value of $564,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. QS Investors LLC acquired a new stake in Portola Pharmaceuticals in the 2nd quarter valued at about $147,000. Oppenheimer Asset Management Inc. lifted its holdings in Portola Pharmaceuticals by 251.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 2,047 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Portola Pharmaceuticals by 54.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 1,141 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in Portola Pharmaceuticals during the third quarter valued at about $178,000. Finally, Sei Investments Co. purchased a new stake in Portola Pharmaceuticals during the third quarter valued at about $217,000. 87.29% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/12/q1-2018-eps-estimates-for-portola-pharmaceuticals-inc-ptla-cut-by-oppenheimer.html.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.